Overview

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Status:
Completed

Trial end date:
2018-03-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to estimate the proportion of participants fulfilling criteria for symptomatic remission following a transition to 12 months treatment with flexible-dose paliperidone palmitate 3 month formulation (PP3M) in participants with schizophrenia previously adequately treated with paliperidone palmitate 1 month formulation (PP1M) for at least 4 months.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Cilag Ltd.

Treatments:

Paliperidone Palmitate